← All indications
Histiocytoma
A neoplasm containing HISTIOCYTES. Important forms include BENIGN FIBROUS HISTIOCYTOMA; and MALIGNANT FIBROUS HISTIOCYTOMA.
Subtype terms (2)
More specific conditions that are subtypes of Histiocytoma in the MeSH hierarchy.
- Histiocytoma, Benign Fibrous
1 drug approved
- Histiocytoma, Malignant Fibrous
3 drugs (2 approved, 1 experimental)
Drugs by status
Phase 2 trials (4)
Organizations
Organization Involved with Phase 3 Indications (13)
- National Cancer Institute (NCI)
- Children's Cancer and Leukaemia Group
- Cooperative Weichteilsarkom Study Group
- European Paediatric Soft Tissue Sarcoma Study Group
- University of Manchester
- University of Milan
- University of Padova
- University of Bristol
- Dutch Childhood Oncology Group
- Societe Internationale d'Oncologie Pediatrique (SIOP)
- University of Ulm
- Erasmus University Rotterdam
- Italian Association for Pediatric Hematology Oncology
Organization Involved with Phase 2 Indications (15)
- Celgene
- Genentech
- Pfizer
- Oncolytics Biotech
- National Institutes of Health (NIH)
- Cornell University
- Harvard University
- Northwestern University
- University of South Florida
- University of Toronto
- Wake Forest University
- University of California, Los Angeles
- Washington University in St. Louis
- National Comprehensive Cancer Network
- St. Jude Children's Hospital
Organization Involved with Phase 1 Indications (1)
Organization Involved with Other Experimental Indications (1)